

DISCLAIMER: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



September 28, 2026

To whom it may concern,

Company name: Heartseed Inc.
Representative: Keiichi Fukuda, MD/PhD/FACC,
CEO, Representative Director of the Board
Securities code: 219A, Tokyo Stock Exchange
Inquiries: Akira Masuda, Head of Strategic Finance
and IR Department
TEL: +81-(0)3-6665-8068 (IR)

Notice Regarding Acquisition of Marketing Authorization Holder License for Regenerative Medical Products

Heartseed Inc. (the "Company") hereby announces that, as previously disclosed in the "Notice Regarding Application for Marketing Authorization Holder License for Regenerative Medical Products" dated August 17, 2026, the Company has obtained the "Marketing Authorization Holder License for Regenerative Medical Products" (the "License") from the Tokyo Metropolitan Government.

The Company is currently advancing the development of allogeneic iPS cell-derived cardiomyocyte spheroids for the treatment of severe heart failure, with plans to apply for marketing authorization approval and subsequently launch the product commercially in Japan. With the acquisition of the License, upon obtaining marketing authorization approval for its product under development, the Company will appropriately conduct marketing operations in Japan in line with GVP and GQP standards.

With the acquisition of the License, the Company will further accelerate the establishment of an operational framework toward future commercialization in Japan, while remaining committed to ensuring compliance with relevant pharmaceutical laws and regulations.

There is no revision to the latest earnings forecast for the fiscal year ending December 31, 2026.

(Cautionary notice on forward-looking information)

The financial results forecasts and other forward-looking information contained in this document are based on the information currently available to the Company and certain assumptions considered reasonable by the Company. It is not a guarantee that the forecasts will be achieved, and actual results may differ significantly from such forecasts depending on various factors.